Miro Sciences Clears TGA Audit of Partner
The Australian regulator's inspection covered production of Miro's StemSmart cell therapy at Q-Gen's Brisbane facility.
Updated on Nov. 12, 2026 in Biotech

The Therapeutic Goods Administration has completed an audit of Q-Gen Cell Therapeutics' facilities in Brisbane, covering production of Miro Sciences' StemSmart product. Miro says it plans a phase two trial of StemSmart in refractory Crohn's disease before the end of 2026.
Why it matters
The inspection was a required step in scaling up manufacturing of a late-stage biological therapy in Australia. Clearing it moves StemSmart closer to clinical testing in patients with a difficult-to-treat form of Crohn's disease.
The evidence is a TGA manufacturing audit and earlier phase two results reported by the company, with a previous trial recording a 78 per cent overall clinical response rate. Whether the planned phase two trial will replicate those results has not been established.
The players
Miro Sciences
A Perth-based biotechnology company that acquired the StemSmart platform, which was developed at Royal Perth Hospital, and is planning its phase two clinical trial.
Q-Gen Cell Therapeutics
A Brisbane cell therapy manufacturer with about 25 years of industry experience, holding its own TGA licence and operating 13 dedicated cleanrooms.
Therapeutic Goods Administration
Australia's federal regulator of medicines and medical devices, which completed the audit of Q-Gen's facilities.
The details
The TGA audited Q-Gen Cell Therapeutics, a Brisbane company that holds its own TGA licence for cell therapy manufacturing and operates 13 dedicated cleanrooms. StemSmart was developed at Royal Perth Hospital using adult human donor bone marrow stem cells and uses a patented process designed to enhance their therapeutic activity.
Timeline
Mid-2025: Miro acquired the StemSmart technology platform.
October 2025: Miro received positive FDA feedback following a Pre-IND meeting.
12 November 2026: The TGA audit clearance of Q-Gen was publicly reported.
Before the end of 2026: Miro aims to begin its phase two trial in Crohn's disease.
Big Picture
More than 70 per cent of stem-cell trials for inflammatory bowel disease worldwide use mesenchymal stromal cells, and StemSmart is one such candidate moving toward phase two testing. The TGA audit is a manufacturing step that clears one of the hurdles for that approach in Australia.
For people with refractory Crohn's disease, a clinical trial would be a possible new treatment route, though no approved therapy is available yet. Patients and families should discuss trial eligibility with their specialist once enrolment details are announced.
The takeaway
Regulatory milestones such as manufacturing audits are necessary before any cell therapy can move into later-stage trials. Readers following Crohn's disease treatment can watch for trial registration updates as the phase two plans progress.
What happens next
Miro aims to begin its phase two trial of StemSmart in refractory Crohn's disease before the end of 2026, subject to regulatory approvals in Australia and the United States.
Further reading
Explore more coverage of Biotech developments shaping treatment options in Australia.
Source note: This article includes information reported by The Sydney Morning Herald.










